General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Metrics and reporting

At Novartis, we are committed to transparent reporting - a central part of our commitment to corporate responsibility.

Our Annual Report serves as our primary reporting mechanism for corporate responsibility, and we have published a combined financial and CR report since 2000.

Our Corporate Responsibility Performance Report consolidates the company’s CR reporting, details our progress and demonstrates our commitment to be a leader in corporate responsibility.

Our CR Performance Report is structured in accordance with the Global Reporting Initiative’s G4 Guidelines, with disclosure at Core application level. We also report a number of additional indicators beyond the requirements for Core level.

As a LEAD participant and a signatory to the United Nations Global Compact (UNGC), this report also fulfills our commitment to produce a UNGC Communication on Progress, a public disclosure outlining our progress in implementing the 10 principles of the UNGC. As a result, in the future we will no longer publish separate GRI, HSE and UNGC Communication on Progress reports.

We also publish:

Review our previous CR reports